Merck & Co Inc
MRK
NYSE
Pharmaceuticals
$148.99
USD
-3.21 (-2.11%)
At close: Aug 20, 2026, 4:00 PM EDT
Market Cap $329.55B
Volume 16.0M
About Merck & Co Inc
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Rahway, New Jersey and currently employs 75,000 full-time employees. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The firm sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
CEO
Mr. Robert Davis
HQ
Rahway, NEW JERSEY, US
Founded
1941
Employees
75,000
Quantli Score
8.4
Outperform
Fin. Health
8.1
Profitability
7.6
Growth
9.0
Cash-Flow Q.
8.8
Key Metrics
7 metrics our research team weighs before forming a view on MRK.
Based on Quantli research · SEC filings · as of Q2 2026
METRIC
VALUE
CHANGE
TREND (3Y)
Revenue Growth (TTM)
4.6%
+2.8 pp
Gross Margin (TTM)
73.0%
-3.6 pp
Operating Margin (TTM)
9.6%
-20.4 pp
Net Margin (TTM)
4.8%
-21.0 pp
ROE (TTM)
7.5%
-25.9 pp
EPS Growth (TTM)
-80.7%
-101.1 pp
Free Cash Flow (TTM)
$16.06B
+9.1%
Financial Snapshot
Revenue
$66.57B
+4.6%
YoY
Gross Margin
73%
TTM
-4.7%
YoY
Net Income
$3.17B
-80.7%
YoY
Operating Cash Flow
$19.97B
+7.7%
YoY
Key Statistics
Open
$150.78
Previous Close
$152.20
Day Range
$148.52 - $152.51
52 Week Range
$77.58 - $153.50
Volume
16.0M
Average Volume (10 Days)
10.4M
Dividend Yield
2.50%
Valuation Measurement
Market Cap
$329.55B
P/E Ratio (TTM)
103.86
P/S Ratio (TTM)
4.95
Price / Book
7.85
Financial Highlights
Profit Margin
4.8%
Return on Assets
2.4%
Return on Equity
7.5%
Revenue (TTM)
$66.57B
Net Income (TTM)
$3.17B
Diluted EPS (TTM)
$1.25
Total Cash (MRQ)
$6.85B
Levered FCF (TTM)
$16.06B
Turn research into action
Knowing a stock is strong is the start. Knowing how to invest in it when you spot good research is good returns.
Earnings Calendar
Next Earnings
Estimated Q3 Release
Oct 29
Est. EPS
Adjusted consensus estimate
$2.25
Analyst Consensus
Based on 5 analyst ratings
Avg Target: $152.60
(+2.4% upside)
High: $179.00 · Low: $141.00
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%